New developments in diagnosis and treatment of infection in orthopedic implants

Clinical Infectious Diseases

Volumn 33, Issue 5 SUPPL. 2, 2001, Pages

  Widmer, A F ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; FUSIDIC ACID; OFLOXACIN; RIFAMPICIN;

ARTHRITIS; CONFERENCE PAPER; DEVICE REMOVAL; FRACTURE; HISTOPATHOLOGY; IMPLANT; INFECTION RISK; INFECTION SENSITIVITY; PRIORITY JOURNAL; SURGICAL INFECTION;

EID: 0035451114     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321863     Document Type: Conference Paper

References (101)

1. Total hip arthroplasty sepsis: Prevention and diagnosis
2. Prosthetic joint infections
3. Total knee replacement: The joint of the decade
4. Efficacy of antibiotics alone for orthopaedic device related infections
5. Air contamination during total hip arthroplasty in an ultraclean air enclosure using different types of staff clothing
6. Surgical antibiotic prophylaxis
7. Controlled release of antibiotics from coated orthopedic implants
8. The prevention of orthopaedic implant and vascular graft infections
9. Physical and biological effects of a surface coating procedure on polyurethane catheters
10. Diagnosis of infection following total hip arthroplasty
11. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial
12. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention
13. Prosthetic joint infection: When can prosthesis salvage be considered?
14. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants
15. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations
16. Host-bacteria interactions in foreign body infections
17. Salmonella infection in total hip replacement: Tests to predict the outcome of antimicrobial therapy
18. Biomaterial-centered infection: Microbial adhesion versus tissue integration
19. Role of cell surface contact in the kinetics of superoxide production by granulocytes
20. Transposon mutants of Staphylococcus epidermidis deficient in elaboration of capsular polysaccharide/adhesin and slime are avirulent in a rabbit model of endocarditis
21. Bacterial biofilms: A common cause of persistent infections
22. Prevention and control of bacterial infections associated with medical devices
23. The involvement of cell-to-cell signals in the development of a bacterial biofilm
24. Small colony variants in staphylococcal infections: Diagnostic and therapeutic implications
25. The slime of coagulase-negative staphylococci: Biochemistry and relation to adherence
26. Adherence characteristics of coagulase-negative staphylococci isolated from patients with infective endocarditis
27. Characterization of clinically significant strains of coagulase-negative staphylococci
28. Update on clinical significance of coagulase-negative staphylococci
29. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections
30. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections
31. Testing antimicrobial susceptibilities of adherent bacteria by a method that incorporates guidelines of the National Committee for Clinical Laboratory Standards
32. Efficacy of ciprofloxacin in stationary-phase bacteria in vivo
33. Practical measures to control device-related bacterial infections
34. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth
35. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics
36. Treatment of infections occurring in total hip surgery
37. Prevention and management of infection after total joint replacement
38. Treatment of infection with debridement and retention of the components following hip arthroplasty
39. Infection after total hip arthroplasty: A study of the treatment of one hundred and six infections
40. Guideline for prevention of surgical site infection, 1999
41. Risk factors for prosthetic joint infection: Case-control study
42. Salvage of infected orthopedic devices
43. Infections of hip prosthesis and artificial joints
44. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene
45. The value of aspiration of the hip joint before revision total hip arthroplasty
46. Evaluation and treatment of infection at the site of a total hip or knee arthroplasty
47. The value of preoperative aspiration before total knee revision
48. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients?
49. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties
50. The diagnostic value of C-reactive protein in infected total hip arthroplasties
51. Diagnosing infection in hip replacements. The use of fine-needle aspiration and radiometric culture
52. Erythrocyte sedimentation rate in infection of total hip replacements
53. The role of intraoperative gram stain in the diagnosis of infection during revision total hip arthroplasty
54. The role of intraoperative frozen sections in revision total joint arthroplasty
55. Bone scan, gallium scan, and hip aspiration in the diagnosis of infected total hip arthroplasty
56. Comparison of indiumlabeled-leukocyte imaging with sequential technetium-gallium scanning in the diagnosis of low-grade musculoskeletal sepsis: A prospective study
57. Evaluation of the painful prosthetic joint. Relative value of bone scan, sedimentation rate, and joint aspiration
58. White cell scans and infected joint replacements. Failure to detect chronic infection
59. Detection of occult infection following total joint arthroplasty using sequential technetium-99m HDP bone scintigraphy and indium-111 WBC imaging
60. Role of technetium-99m phosphonate bone and indium-111 leukocyte scanning for detecting the infected hip prosthesis
61. Infected knee prosthesis: Diagnosis with In-111 leukocyte, Tc-99m sulfur colloid, and Tc-99m MDP imaging
62. Diagnosis of infection by preoperative scintigraphy with indium-labeled white blood cells
63. Hip and knee arthroplasty infection: In-111-IgG scintigraphy in 102 cases
64. Diagnosis of bone, joint, and joint prosthesis infections with In-111-labeled nonspecific human immunoglobulin G scintigraphy
65. Infectious imaging with indium-111-labeled nonspecific polyclonal human immunoglobulin
66. Simultaneous administration of 99Tcm-HMPAO-labelled autologous leukocytes and 111In-labelled non-specific polyclonal human immunoglobulin G in bone and joint infections
67. Frozen histologic section as a guide to sepsis in revision joint arthroplasty
68. Analysis of frozen sections of intraoperative specimens obtained at the time of reoperation after hip or knee resection arthroplasty for the treatment of infection
69. Diagnosis of infection by frozen section during revision arthroplasty
70. An assessment of the histological criteria used to diagnose infection in hip revision arthroplasty tissues
71. Gram stain detection of infection during revision arthroplasty
72. Efficacy of preoperative hip aspiration performed in the radiology department
73. Hip aspiration: A cost effective and accurate method of evaluating the potentially infected hip prostheses
74. Aspiration of the hip joint before revision total hip arthroplasty: Clinical and laboratory factors influencing attainment of a positive culture
75. Aspiration arthrography of the hip joint: Its uses and limitations in revision hip surgery
76. Aspiration as a guide to sepsis in revision total hip arthroplasty
77. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty
78. Erythrocyte sedimentation rate and C-reactive protein values in patients with total hip arthroplasties
79. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty
80. Diagnostic value of sinus-tract cultures in chronic osteomyelitis
81. Improved detection of infection in hip replacements: A currently underestimated problem
82. Detection of Staphylococcus aureus and Staphylococcus epidermidis in clinical samples by 16S rRNA-directed in situ hybridization
83. The pathology of the joint tissues and its clinical relevance in prosthesis failure
84. The reliability of analysis of intraoperative frozen sections for identifying active infection during revision hip or knee arthroplasty
85. Hip implant infection. Treatment with resection arthroplasty and late total hip arthroplasty
86. Two-stage reconstruction of a total hip arthroplasty because of infection
87. Orthopedic prosthesis salvage
88. Treatment of infection at the site of total hip replacement
89. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole)
90. Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination
91. Prosthetic device infections
92. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin
93. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
94. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa
95. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa
96. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
97. One-stage revision surgery of the infected hip: A minimum 10-year follow-up study
98. Direct-exchange arthroplasty for the treatment of infection after total hip replacement: An average ten-year follow-up
99. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses
100. Infection after total knee arthroplasty: A retrospective study of the treatment of eighty-one infections